who should not use glp-1 Researchers find medications safe to continue before surgery in patients with diabetes and obesity Everyone's got an opinion on

For many others, there's a better one

Patient Cost Sharing Library The Complex Web Behind Low Persistence Low persistence in GLP-1 therapy is rarely the result of a single factor

A recent composition for the Obesity Medicine Association titled "A New Path Forward" highlights struggles people living with obesity face, and has been viewed over 4,000 times

Here's what operators can claim, and what to actually stock.

A recent study links use of weight-loss drugs like Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, or Zepbound to vision loss in patients.

This review will outline the physiology and pharmacological potential of amylin and GLP-1, respectively, and focus on innovative peptide drug development leading to drugs acting on two or more distinct receptors, such as an amylin and GLP-1 peptide hybrid, potentially producing a more effective treatment strategy to combat the rapidly increasing global obesity.